As of Mar 30
| +0.30 / +2.21%|
The 14 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 19.50, with a high estimate of 45.00 and a low estimate of 14.00. The median estimate represents a +40.59% increase from the last price of 13.87.
The current consensus among 17 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.